109
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Comment on ‘‘how does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria?’’: reply from author

&
Page 73 | Received 18 Dec 2019, Accepted 20 Dec 2019, Published online: 12 Jan 2020

References

  • Cosansu NC. Hematological parameters in patients with chronic spontaneous urticaria. Cutan Ocul Toxicol 2019:1–3.
  • Akdogan N, Demirel Ogut N, Dogan S, Atakan N. Long-term effects of omalizumab on peripheral blood cells and C-reactive protein levels in patients with chronic spontaneous urticaria. Dermatol Ther 2019;32:e12966.
  • Sariçam G. Neutrophil/lymphocyte, platelet/lymphocyte and neutrophil/monocyte rates in carpal tunnel syndrome. Turkiye Klinikleri J Cardiovasc Sci 2018;30:107–112.
  • Xiao Q, Zhang B, Deng X, et al. The preoperative neutrophil-to-lymphocyte ratio is a novel immune parameter for the prognosis of esophageal basaloid squamous cell carcinoma. PLoS One 2016;11:e0168299.
  • Shi J, Zhao W, Ying H, et al. The relationship of platelet to lymphocyte ratio and neutrophil to monocyte ratio to radiographic grades of knee osteoarthritis. Z Rheumatol 2018;77:533–537.
  • Önder S, Ozturk M. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria? Cutan Ocul Toxicol 2019;6:1–5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.